A health technology company Nightingale Health announced Thursday the performance of its next-generation disease risk predictions, which will be launched in Singapore and the United States.
According to the company’s press release, the performance of Nightingale Health disease risk predictions is as good or better than the performance of current routine healthcare tools.
“However, Nightingale Health’s test is significantly different from other tests, as it only requires one blood sample and age and gender as background information,” the release states.
The company says it will launch in Singapore and the United States the new disease risk predictions for metabolic fatty liver disease and cerebral infarction, which are part of the Health Check product family.